Skip to content

Study · Animal study (in vivo) · rat · 1999

5 results

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.

Xu G, Stoffers DA, Habener JF, Bonner-Weir S

Diabetes1 Dec 1999Cited by 884 (Europe PMC)

PMID10580413 (opens in a new tab)DOI10.2337/diabetes.48.12.2270 (opens in a new tab)PepBankPUB-10580413
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rats, exendin‑4 stimulated beta-cell differentiation from ductal progenitor cells.

    In plain wordsIn rats, exendin‑4 stimulated the formation of beta-cells from ductal progenitor cells.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseBeta-cell neogenesis
    Study

    ratn: not reported in source

    partial pancreatectomy rat model of type 2 diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 10 days post-pancreatectomyAs given in this study (rat).

    Source sentences

    Summary
    Here we report that exendin-4, a long-acting GLP-I agonist, stimulates both the differentiation of beta-cells from ductal progenitor cells (neogenesis) and proliferation of beta-cells when administered to rats.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats, exendin‑4 stimulated beta-cell proliferation.

    In plain wordsIn rats, exendin‑4 stimulated beta-cell proliferation.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseBeta-cell proliferation
    Study

    ratn: not reported in source

    partial pancreatectomy rat model of type 2 diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 10 days post-pancreatectomyAs given in this study (rat).

    Source sentences

    Summary
    Here we report that exendin-4, a long-acting GLP-I agonist, stimulates both the differentiation of beta-cells from ductal progenitor cells (neogenesis) and proliferation of beta-cells when administered to rats.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In partially pancreatectomized rats, daily exendin‑4 attenuated the development of diabetes.

    In plain wordsIn rats with partial pancreas removal, daily exendin‑4 reduced the development of diabetes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseDevelopment of diabetes
    Study

    ratn: not reported in source

    partial pancreatectomy rat model of type 2 diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 10 days post-pancreatectomyAs given in this study (rat).

    Source sentences

    Summary
    In a partial pancreatectomy rat model of type 2 diabetes, the daily administration of exendin-4 for 10 days post-pancreatectomy attenuates the development of diabetes.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, exendin‑4 stimulated pancreatic regeneration.

    In plain wordsIn rats, exendin‑4 stimulated pancreas regeneration.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreasePancreatic regeneration
    Study

    ratn: not reported in source

    partial pancreatectomy rat model of type 2 diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 10 days post-pancreatectomyAs given in this study (rat).

    Source sentences

    Summary
    We show that exendin-4 stimulates the regeneration of the pancreas and expansion of beta-cell mass by processes of both neogenesis and proliferation of beta-cells.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats, exendin‑4 expanded beta-cell mass through neogenesis and proliferation.

    In plain wordsIn rats, exendin‑4 increased beta-cell mass.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseBeta-cell mass
    Study

    ratn: not reported in source

    partial pancreatectomy rat model of type 2 diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 10 days post-pancreatectomyAs given in this study (rat).

    Source sentences

    Summary
    We show that exendin-4 stimulates the regeneration of the pancreas and expansion of beta-cell mass by processes of both neogenesis and proliferation of beta-cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.